> GlaxoSmithKline has returned Paxil CR to the market, three months after regulators found manufacturing problems at three of its facilities. Story [1]
> A European drug panel has recommended Roche's Tarceva for lung cancer. Story [2]
> The European Medicines Agency has recommended the continued suspension of Pfizer's Bextra with new warnings regarding all Cox-2 inhibitors. Story [3]
> Neurobiological Technologies has signed a manufacturing deal with Baxter and Nordmark for a Phase III trial of Viprinex. Release [4]
> Switzerland's Debiopharm and Neovacs have signed an equity and licensing deal for the development of Neovacs' anti-TNF-Alpha product. Release [5]
> The EU's Committee for Medicinal Products for Human Use has recommended approval of Schering's contrast agent, Vasovist. Article [6]
And Finally... Even as pharmaceutical drugs continue their double-digit rise in prices, generic drug prices are remaining steady. Story [7]
Links:
[1] http://www.washingtonpost.com/wp-dyn/content/article/2005/06/27/AR2005062700472.html
[2] http://www.businessweek.com/ap/financialnews/D8B00TCG2.htm?campaign_id=apn_home_down
[3] http://money.cnn.com/2005/06/27/news/fortune500/pfizer_bextra.reut/
[4] http://biz.yahoo.com/prnews/050627/sfm032.html?.v=14
[5] http://biz.yahoo.com/prnews/050627/ukm014.html?.v=11
[6] http://www.forbes.com/home/feeds/afx/2005/06/27/afx2111686.html
[7] http://www.usatoday.com/money/industries/health/2005-06-26-generic-usat_x.htm?POE=MONISVA